Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The EMBRACE Trial: Eisai Metastatic BReast cancer study Assessing physician's Choice versus E7389. A phase III open label, randomized, parallel, two-arm, multi-center study of E7389 [eribulin] versus 'treatment of physician's choice' in patients with locally recurrent, metastatic breast cancer, previously treated with at least two and a maximum of five prior chemotherapy regimens, including an anthracycline and a taxane

Next Previous
Trial Profile

The EMBRACE Trial: Eisai Metastatic BReast cancer study Assessing physician's Choice versus E7389. A phase III open label, randomized, parallel, two-arm, multi-center study of E7389 [eribulin] versus 'treatment of physician's choice' in patients with locally recurrent, metastatic breast cancer, previously treated with at least two and a maximum of five prior chemotherapy regimens, including an anthracycline and a taxane

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer; Carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms EMBRACE
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 10 Dec 2022 Results of post-hoc analysis of two studies (Studies 305 and 301) comparing ibulin with otherchemotherapeutic agents (treatment of physicians choice and capecitabine, respectively[control]) in patients with both HER2-low and HER2-0 metastatic breast cancer, presented at the 45th Annual San Antonio Breast Cancer Symposium.
    • 01 Dec 2022 According to an Eisai Inc media release, a post hoc subgroup analysis from the trial will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS).
    • 13 Sep 2022 Results of post-hoc analysis of three trials (NCT00388726, NCT00337103 and NCT02225470) assessing efficacy of eribulin mesylate in HER2-low metastatic breast cancer, presented at the 47th European Society for Medical Oncology Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top